NasdaqCM:CEMI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Chembio Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CEMI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.9%

CEMI

-0.7%

US Medical Equipment

-1.3%

US Market


1 Year Return

-11.1%

CEMI

24.8%

US Medical Equipment

18.5%

US Market

Return vs Industry: CEMI underperformed the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: CEMI underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

CEMIIndustryMarket
7 Day2.9%-0.7%-1.3%
30 Day1.7%4.8%5.3%
90 Day-4.1%6.5%7.5%
1 Year-11.1%-11.1%25.9%24.8%21.3%18.5%
3 Year-20.2%-20.2%75.1%70.6%42.4%32.9%
5 Year0.4%0.4%150.5%131.0%84.2%63.5%

Price Volatility Vs. Market

How volatile is Chembio Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Chembio Diagnostics undervalued compared to its fair value and its price relative to the market?

2.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CEMI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CEMI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: CEMI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CEMI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CEMI is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Chembio Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

45.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CEMI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CEMI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CEMI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CEMI's revenue (26% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: CEMI's revenue (26% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Chembio Diagnostics performed over the past 5 years?

-24.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CEMI is currently unprofitable.

Growing Profit Margin: CEMI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CEMI is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.

Accelerating Growth: Unable to compare CEMI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CEMI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).


Return on Equity

High ROE: CEMI has a negative Return on Equity (-52.96%), as it is currently unprofitable.


Next Steps

Financial Health

How is Chembio Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: CEMI's short term assets ($53.9M) exceed its short term liabilities ($14.3M).

Long Term Liabilities: CEMI's short term assets ($53.9M) exceed its long term liabilities ($24.9M).


Debt to Equity History and Analysis

Debt Level: CEMI's debt to equity ratio (46.4%) is considered high.

Reducing Debt: Insufficient data to determine if CEMI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CEMI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CEMI has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 30.3% each year.


Next Steps

Dividend

What is Chembio Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CEMI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CEMI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CEMI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CEMI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CEMI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Richard Eberly (59 yo)

0.58

Tenure

Mr. Richard L. Eberly serves as the President and Chief Executive Officer at Chembio Diagnostics, Inc. since March 16, 2020 and has been its Director since May 02, 2020. He joined Chembio in March, 2020. H ...


Leadership Team

NamePositionTenureCompensationOwnership
Neil Goldman
Executive VP & CFO2.83yrsUS$346.94k0.43%
$ 430.0k
Javan Esfandiari
Executive VP16.75yrsUS$409.98k0.54%
$ 534.1k
Richard Eberly
President0.58yrno datano data
Paul Angelico
Vice President of Global Operations0.75yrno datano data
Charles Caso
Vice President of Sales & Marketing0.33yrno datano data
Konstantin Lyashchenko
Research Director of Chembio Diagnostic Systems Incno dataUS$106.37kno data

0.8yrs

Average Tenure

53yo

Average Age

Experienced Management: CEMI's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Richard Eberly
President0.58yrno datano data
Mary Polan
Independent Director2.17yrsUS$40.50k0.039%
$ 38.2k
John Potthoff
Independent Director2.42yrsUS$44.50k0.19%
$ 185.5k
Katherine Davis
Independent Chairperson6.58yrsUS$73.50k0.40%
$ 396.6k

2.3yrs

Average Tenure

61.5yo

Average Age

Experienced Board: CEMI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.8%.


Top Shareholders

Company Information

Chembio Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chembio Diagnostics, Inc.
  • Ticker: CEMI
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$98.993m
  • Shares outstanding: 20.16m
  • Website: https://chembio.com

Number of Employees


Location

  • Chembio Diagnostics, Inc.
  • 555 Wireless Boulevard
  • Hauppauge
  • New York
  • 11788
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CEMINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2000
D9IABST (Boerse-Stuttgart)YesCommon StockDEEUROct 2000

Biography

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 00:34
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.